CytoMed Therapeutics (GDTC) Operating Leases (2021 - 2025)

CytoMed Therapeutics has disclosed Operating Leases across 5 years of filings, most recently posting $41249.3 for Q4 2025.

• In Q4 2025, Operating Leases rose 138.27% year-over-year to $41249.3; the TTM figure through Dec 2025 stood at $41249.3 (up 138.27% YoY), while the FY2025 annual figure was $19598.0, up 137.21% from the prior year.
• Operating Leases came in at $41249.3 for Q4 2025 at CytoMed Therapeutics, up from $19571.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $41249.3 in Q4 2025 to a low of $2565.0 in Q2 2024.
• Average Operating Leases over 5 years is $13626.2, with a median of $9396.8 recorded in 2021.
• Year-over-year, Operating Leases slumped 65.83% in 2024 and jumped 663.0% in 2025.
• Over 5 years, Operating Leases stood at $11287.7 in 2021, then sank by 57.17% to $4834.3 in 2022, then slipped by 3.11% to $4684.1 in 2023, then soared by 269.59% to $17311.9 in 2024, then soared by 138.27% to $41249.3 in 2025.
• Per Business Quant data, the three most recent Operating Leases figures were $41249.3 in Q4 2025, $19571.0 in Q2 2025, and $17311.9 in Q4 2024.